1092689-33-2

Usage

Uses

Used in Research Laboratories:
(4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine HCL is used as a reagent and building block for the synthesis of various organic compounds, facilitating the creation of new chemical entities and contributing to the advancement of chemical research.
Used in Medical and Pharmaceutical Applications:
In the medical and pharmaceutical industry, (4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine HCL is used as a potential component in drug development due to its unique structure and properties, which may offer novel therapeutic avenues and contribute to the discovery of new medications.
Used in Chemical and Biological Research:
(4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine HCL is utilized in chemical and biological research as an important tool for exploring molecular interactions and mechanisms, potentially leading to breakthroughs in understanding complex biological processes and the development of innovative solutions in science and technology.

Upstream product

• 1380500-93-5 tert-butyl N-[[4-(1,2,4,5-tetrazin-3-yl)phenyl]methyl]carbamate 
• 3473-63-0 formamidine acetic acid 
• 15996-76-6 4-cyanobenzylamine hydrochloride 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 

Downstream Products

• 1225194-71-7 N-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-6-(3-(5,5-difluoro-7-(4-methoxyphenyl)-1,3-dimethyl-5H-4λ⁴,5λ⁴-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-2-yl)propanamido)hexanamide 
• 1225146-51-9 C₂₃H₂₂N₆O₃ 
• 1225194-70-6 N-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-3-(5,5-difluoro-7,9-dimethyl-5H-4λ⁴,5λ⁴-dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-3-yl)propenamide 
• 1225146-53-1 5-(4-(1,2,4,5-tetrazin-3-yl)benzylamino)-5-oxopentanoic acid 
• 1393381-47-9 C₃₄H₂₃N₅O₈ 
• 1393381-54-8 C₃₄H₃₈N₇O⁽¹⁺⁾ 
• 1356191-81-5 C₄₆H₄₈N₈O₇S₂ 
• 1393381-55-9 C₄₁H₃₈N₇O₂⁽¹⁺⁾ 
• 1393381-50-4 C₃₀H₃₃N₈O⁽¹⁺⁾ 
• 1393381-53-7 C₃₄H₂₉N₇O₄ 
• 1286255-39-7 AZD₂₂₈₁-Tz 

Relevant academic research and scientific papers

In Vivo Targeting through Click Chemistry

Targeting small molecules to diseased tissues as therapy or diagnosis is a significant challenge in drug delivery. Drug-eluting devices implanted during invasive surgery allow the controlled presentation of drugs at the disease site, but cannot be modified once the surgery is complete. We demonstrate that bioorthogonal click chemistry can be used to target circulating small molecules to hydrogels resident intramuscularly in diseased tissues. We also demonstrate that small molecules can be repeatedly targeted to the diseased area over the course of at least one month. Finally, two bioorthogonal reactions were used to segregate two small molecules injected as a mixture to two separate locations in a mouse disease model. These results demonstrate that click chemistry can be used for pharmacological drug delivery, and this concept is expected to have applications in refilling drug depots in cancer therapy, wound healing, and drug-eluting vascular grafts and stents.

Genetic Code Expansion Enables Live-Cell and Super-Resolution Imaging of Site-Specifically Labeled Cellular Proteins

Methods to site-specifically and densely label proteins in cellular ultrastructures with small, bright, and photostable fluorophores would substantially advance super-resolution imaging. Recent advances in genetic code expansion and bioorthogonal chemistr

Selective CRAF Inhibition Elicits Transactivation

Discovering molecules that regulate closely related protein isoforms is challenging, and in many cases the consequences of isoform-specific pharmacological regulation remains unknown. RAF isoforms are commonly mutated oncogenes that serve as effector kinases in MAP kinase signaling. BRAF/CRAF heterodimers are believed to be the primary RAF signaling species, and many RAF inhibitors lead to a "paradoxical activation"of RAF kinase activity through transactivation of the CRAF protomer; this leads to resistance mechanisms and secondary tumors. It has been hypothesized that CRAF-selective inhibition might bypass paradoxical activation, but no CRAF-selective inhibitor has been reported and the consequences of pharmacologically inhibiting CRAF have remained unknown. Here, we use bio-orthogonal ligand tethering (BOLT) to selectively target inhibitors to CRAF. Our results suggest that selective CRAF inhibition promotes paradoxical activation and exemplify how BOLT may be used to triage potential targets for drug discovery before any target-selective small molecules are known.

Super-resolution imaging of the Golgi in live cells with a bioorthogonal ceramide probe

We report a lipid-based strategy to visualize Golgi structure and dynamics at super-resolution in live cells. The method is based on two novel reagents: a trans-cyclooctene-containing ceramide lipid (Cer-TCO) and a highly reactive, tetrazine-tagged near-IR dye (SiR-Tz). These reagents assemble via an extremely rapid "tetrazine-click" reaction into Cer-SiR, a highly photostable "vital dye" that enables prolonged live-cell imaging of the Golgi apparatus by 3D confocal and STED microscopy. Cer-SiR is nontoxic at concentrations as high as 2 μM and does not perturb the mobility of Golgi-resident enzymes or the traffic of cargo from the endoplasmic reticulum through the Golgi and to the plasma membrane.

COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET

The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a payload to a ligand bound to a biological target.

CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE

The present disclosure provides click-crosslinked hydrogels and methods of use.